Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3130052 | 0.81 | TP53 (0.44) | TSHRALDH1A1GAACYP2C19POLB | |
| SCHEMBL27845946 | 0.80 | GAA (0.43) | TSHRALDH1A1MAPK1GAACYP2C19 | |
| SCHEMBL3465966 | 0.78 | SMN1; SMN2 (0.39) | ALDH1A1MAPK1POLB | |
| SCHEMBL3466906 | 0.76 | ALDH1A1 (0.35) | ALDH1A1MAPK1POLBKMT2AMEN1 | |
| SCHEMBL3465076 | 0.75 | ALDH1A1 (0.34) | ALDH1A1MAPK1GLAPOLBHSD17B10 | |
| SCHEMBL1299600 | 0.74 | TSHR (0.45) | TSHRALDH1A1MAPK1GAACYP2C19 | |
| SCHEMBL31263394 | 0.74 | TSHR (0.47) | TSHRALDH1A1MAPK1GAACYP2C19 | |
| SCHEMBL31263721 | 0.74 | TSHR (0.47) | TSHRALDH1A1MAPK1GAACYP2C19 | |
| SCHEMBL21670253 | 0.71 | TSHR (0.62) | TSHRALDH1A1MAPK1GAACYP2C19 | |
| SCHEMBL5022233 | 0.71 | TSHR (0.62) | TSHRALDH1A1MAPK1GAACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | TSHR 1193/4885ALDH1A1 523/4885MAPK1 973/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | TSHR 3668/4885ALDH1A1 268/4885MAPK1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.